TGTX
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
Article Summary
BUY- TG Therapeutics Inc. (NASDAQ: TGTX) announced the publication of data from a post-hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI (ublituximab-xiiy) in treatment-naïve adult patients with relapsing forms of multiple sclerosis in Frontiers in Immunology, showing treatment with the drug reduced annualized relapse rate by 56.7% vs. teriflunomide and demonstrated significant improvements across disability, MRI outcomes, and no evidence of disease activity (NEDA-3) supporting early use of high-efficacy therapy in early-stage RMS patients.
- TG Therapeutics's Executive Chairman and Chief Executive Officer Michael S.
- Weiss stated that the findings further reinforce the compelling efficacy profile of BriUMVI, particularly in patients early in their disease journey.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 81.3% | 25% | 100.0 ptsExceptional (81.3%) - Hypergrowth |
| EPS Growth Next 5Y ? | 3.2% | 25% | 10.0 ptsVery Weak (3.2%) - Minimal expectations |
| Target Price Upside ? | 28.6% | 20% | 75.0 ptsSignificant Upside (28.6%) - Target: $48.00 vs Current: $37.33 |
| Gross Margin % ? | 83.1% | 15% | 100.0 ptsExceptional (83.1%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -16.4% | 15% | 40.0 ptsMild Pullback (-16.4%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About TGTX
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
- The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
- The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
- Its research pipeline includes various investigational medicines.
- The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co.
- Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.